These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 1601533)

  • 41. Sample sizes for clinical trials with normal data.
    Julious SA
    Stat Med; 2004 Jun; 23(12):1921-86. PubMed ID: 15195324
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Individual bioequivalence: what matters to the patient.
    Hauck WW; Anderson S
    Stat Med; 1991 Jun; 10(6):959; discussion 959-60. PubMed ID: 1876785
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Experimental design and statistical methods for classical and bioequivalence hypothesis testing with an application to dairy nutrition studies.
    Tempelman RJ
    J Anim Sci; 2004; 82 E-Suppl():E162-172. PubMed ID: 15471796
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Review and use of decision rules for bioequivalence trials].
    Nicolas P; Tod M; Petitjean O
    Therapie; 1993; 48(1):15-22. PubMed ID: 8356540
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sample sizes for batch acceptance from single- and multistage designs using two-sided normal tolerance intervals with specified content.
    Hauck WW; Shaikh R
    J Biopharm Stat; 2001 Nov; 11(4):335-46. PubMed ID: 12018783
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tests for individual and population bioequivalence based on generalized p-values.
    McNally RJ; Iyer H; Mathew T
    Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Testing bioequivalence for multiple formulations with power and sample size calculations.
    Zheng C; Wang J; Zhao L
    Pharm Stat; 2012; 11(4):334-41. PubMed ID: 22692852
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A log-normal model for individual bioequivalence.
    Phillips KF
    J Biopharm Stat; 1993 Sep; 3(2):185-201. PubMed ID: 8220403
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pilot trial for the assessment of relative bioavailability in generic drug product development: statistical power.
    Wang Y; Zhou S
    J Biopharm Stat; 1999 Mar; 9(1):179-87. PubMed ID: 10091917
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A group sequential approach to crossover trials for average bioequivalence.
    Hauck WW; Preston PE; Bois FY
    J Biopharm Stat; 1997 Mar; 7(1):87-96. PubMed ID: 9056590
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discussion of individual bioequivalence by M.-L. Chen.
    Gould AL
    J Biopharm Stat; 1997 Mar; 7(1):23-9. PubMed ID: 9056584
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Power of the two one-sided tests procedure in bioequivalence.
    Phillips KF
    J Pharmacokinet Biopharm; 1990 Apr; 18(2):137-44. PubMed ID: 2348380
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exact calculation of power and sample size in bioequivalence studies using two one-sided tests.
    Shen M; Russek-Cohen E; Slud EV
    Pharm Stat; 2015; 14(2):95-101. PubMed ID: 25477145
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lack of pharmacokinetic interaction as an equivalence problem.
    Steinijans VW; Hartmann M; Huber R; Radtke HW
    Int J Clin Pharmacol Ther Toxicol; 1991 Aug; 29(8):323-8. PubMed ID: 1835963
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An approximate approach to sampling size determination for the equivalence hypothesis.
    Hsieh CY; Liu JP
    J Biopharm Stat; 2013 May; 23(3):526-38. PubMed ID: 23611193
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Determining equivalence and the impact of sample size in anti-infective studies: a point to consider.
    Bristol DR
    J Biopharm Stat; 1996 Jul; 6(3):319-26. PubMed ID: 8854235
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Consideration of individual bioequivalence.
    Anderson S; Hauck WW
    J Pharmacokinet Biopharm; 1990 Jun; 18(3):259-73. PubMed ID: 2380920
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sample size determination for the two one-sided tests procedure in bioequivalence.
    Liu JP; Chow SC
    J Pharmacokinet Biopharm; 1992 Feb; 20(1):101-4. PubMed ID: 1588502
    [No Abstract]   [Full Text] [Related]  

  • 60. On the use of the ratio or the odds ratio of cure rates in therapeutic equivalence clinical trials with binary endpoints.
    Tu D
    J Biopharm Stat; 1998 May; 8(2):263-82. PubMed ID: 9598422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.